Known targets — ChEMBL curated mechanism
ABL1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB2AGTR1BCL2BCL2A1BCL2L1BCL2L10BCL2L2BCRBRAFCHRM1CHRNA10CHRNA9DRD1DRD2DRD3DRD4DRD5EGFRF2FLT1FLT4GCKGHSRGNRHRGRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BHTR1AHTR1BHTR1DHTR2AHTR2CHTR3AIDH2KDRKITMAOBMCL1MTTPPP4HBPDGFRBPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PIKFYVEROCK1ROCK2SLC18A2SLC6A2SLC6A3SLC6A4TACR1TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8gyrAgyrBparCparEpol
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MMP1 | P03956 | 1/20 | 0.49 |
| ▸ | MMP9 | P14780 | 1/20 | 0.49 |
| ▸ | MMP13 | P45452 | 1/20 | 0.49 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3341840 | 1.00 | SIGMAR1 (0.62) | SIGMAR1HTTMEN1KMT2AL3MBTL1 | |
| SCHEMBL3346880 | 1.00 | SIGMAR1 (0.62) | SIGMAR1HTTMEN1KMT2AL3MBTL1 | |
| SCHEMBL593666 | 0.92 | SIGMAR1 (0.74) | SIGMAR1HTTMEN1KMT2AL3MBTL1 | |
| SCHEMBL8092326 | 0.92 | SIGMAR1 (0.74) | SIGMAR1HTTMEN1KMT2AL3MBTL1 | |
| SCHEMBL2795948 | 0.92 | SIGMAR1 (0.74) | SIGMAR1HTTMEN1KMT2AL3MBTL1 | |
| SCHEMBL719011 | 0.92 | SIGMAR1 (0.74) | SIGMAR1HTTMEN1KMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL1134233 | 0.90 | SIGMAR1 (0.72) | SIGMAR1HTTMEN1KMT2AL3MBTL1 | |
| Hydrochloric Acid SCHEMBL1134234 | 0.90 | SIGMAR1 (0.72) | SIGMAR1HTTMEN1KMT2AL3MBTL1 | |
| SCHEMBL6539539 | 0.90 | SIGMAR1 (0.59) | SIGMAR1HTTMEN1KMT2AL3MBTL1 | |
| SCHEMBL3630860 | 0.86 | SIGMAR1 (0.57) | SIGMAR1MEN1KMT2AL3MBTL1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2172443-B1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE | HAMARI CHEMICALS LTD (JP) | 2013-03-27 | — | — | EP | disclosed |
| US-8222452-B2 | Method for producing optically active amines | HAMARI CHEMICALS, LTD. (JP) | 2012-07-17 | — | — | US | disclosed |
| US-20100160636-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES | HAMARI CHEMICALS, LTD. (JP) | 2010-06-24 | — | — | US | disclosed |
| EP-2172443-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINE | Hamari Chemicals, Ltd. (JP) | 2010-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160636-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE AMINES | INMT, HNMT, PADI3 | SIGMAR1 943/4885HTT 527/4885MEN1 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.